The incorporation of mTOR inhibitors to curb tumor progression in kidney transplant recipients (KTRs) appears promising with respect to overall survival, although definitive outcomes for complex RCC remain undetermined [88]. The gene discussed is MTOR; the disease is renal cell carcinoma.